Advanced search
Publication Cover
Cancer Investigation Volume 16, 1998 - Issue 7
Submit an article Journal homepage
13
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Pyrazoloacridine for the Treatment of Hormone-Refractory Prostate Cancer

Eric J. Small Department of Medicine, University of California at San Francisco, San Francisco, California; Department of Urology, University of California at San Francisco, San Francisco, CaliforniaCorrespondence[email protected]
,
Linda J. Fippin Department of Medicine, University of California at San Francisco, San Francisco, California; Department of Urology, University of California at San Francisco, San Francisco, California
&
Sarah P. Whisenant Department of Medicine, University of California at San Francisco, San Francisco, California; Department of Urology, University of California at San Francisco, San Francisco, California
Pages 456-461 | Published online: 11 Jun 2009

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

William A Denny. (2004) Emerging DNA topoisomerase inhibitors as anticancer drugs. Expert Opinion on Emerging Drugs 9:1, pages 105-133.
Read now

Articles from other publishers (9)

Bhuvaneswari Ramaswamy, Ewa Mrozek, John Philip Kuebler, Tanios Bekaii-Saab & Eric H. Kraut. (2009) Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. Investigational New Drugs 29:2, pages 347-351.
Crossref
Neil Senzer, James Arsenau, Donald Richards, Barry Berman, John R. MacDonald & Sheri Smith. (2005) Irofulven Demonstrates Clinical Activity Against Metastatic Hormone-Refractory Prostate Cancer in a Phase 2 Single-Agent Trial. American Journal of Clinical Oncology 28:1, pages 36-42.
Crossref
Amelia Magnano, Silvia Sparapani, Roberta Lucciarini, Mosca Michela, Consuelo Amantini, Giorgio Santoni & Ippolito Antonini. (2004) Synthesis and biological evaluation of indazolo[4,3-bc][1,5]naphthyridines (10-aza-pyrazolo[3,4,5-kl]acridines): a new class of antitumor agents. Bioorganic & Medicinal Chemistry 12:22, pages 5941-5947.
Crossref
Joel M. Reid, Denise L. Walker, Jennifer K. Miller, Linda M. Benson, Andrew J. Tomlinson, Stephen Naylor, April L. Blajeski, Patricia M. LoRusso & Matthew M. Ames. (2004) The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes. Clinical Cancer Research 10:4, pages 1471-1480.
Crossref
YanPing Hu, Awtar Krishan, WeiJia Nie, Kasi S. Sridhar, Lawrence D. Mayer & Marcel Bally. (2004) Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide, and Topotecan in Drug-Resistant Tumor Cells. Clinical Cancer Research 10:3, pages 1160-1169.
Crossref
Alex A. Adjei, Joel M. Reid, Charles Erlichman, Jeff A. Sloan, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Lorelei J. Hanson, Stacie Ruben, Scott A. Boerner, Pamela Atherton, Matthew M. Ames & Scott H. Kaufmann. (2002) A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer. Investigational New Drugs 20:3, pages 297-304.
Crossref
S. Culine & J.-P. Droz. (2000) Chemotherapy in advanced androgen-independent prostate cancer 1990–1999: A decade of progress?. Annals of Oncology 11:12, pages 1523-1530.
Crossref
Wei-Dong Chen, James R. Eshleman, M. Reza Aminoshariae, Ai-Hong Ma, Neil Veloso, Sanford D. Markowitz, W. David Sedwick & Martina L. Veigl. (2000) Cytotoxicity and Mutagenicity of Frameshift-Inducing Agent ICR191 in Mismatch Repair-Deficient Colon Cancer Cells. JNCI: Journal of the National Cancer Institute 92:6, pages 480-485.
Crossref
Alex A. Adjei. (1999) Current status of pyrazoloacridine as an anticancer agent. Investigational New Drugs 17:1, pages 43-48.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.